Timo K. van den Berg
Company: Byondis
Job title: Senior Director Immuno- Oncology
Seminars:
Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm
Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more
day: Innate Immune Checkpoints & Activation Pre-Focus Day
The CD47-SIRPα Myeloid Checkpoint in Cancer & its Therapeutic Targeting with BYON4228 11:30 am
day: Innate Immune Checkpoints & Activation Pre-Focus Day